

MEDIA RELEASE

Brazilian Patent Application approved for granting

Sydney, Australia 19 January 2021 – Azure Health Technology Limited (AZT), the Company commercialising an innovative non-invasive and direct drug and vitamin delivery platform, is pleased to announce that the Brazilian Patent Office has approved a patent application titled: 'Transmucosal delivery of tocotrienols' for granting.

The patent application is directed to compositions formulated for transmucosal delivery of tocotrienols for promoting the treatment or prevention of post exercise muscle soreness, delayed onset muscle soreness, and improving exercise endurance and performance. Patent claims are also directed at reducing inflammation, cardiac fibrosis and treatment of cancer amongst other claims. Once granted, this patent will provide patent rights in Brazil until 2033.

Dr Glenn Tong, the Chief Executive Officer and Managing Director of AZT, said "Along with corresponding patents granted in the US, Canada, the European Union, Japan, China, Australia, New Zealand, Singapore and South Africa, the grant of this Brazilian patent will provide AZT with a growing patent estate spanning major markets which supports our global commercialisation strategy for both our drug development program and nutraceuticals business."

For more information please contact:

Dr Glenn Tong
CEO and Managing Director
Tel: +61 (0) 412 193 350

Ms Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200

About Azure Health Technology Limited

Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: www.azureht.com.au
